Sustained-release Ophthalmology Product

Overview

This investigational ophthalmology product is an injectable drug incorporating DURECT’s sustained-release SABER® technology. The active pharmaceutical ingredient and indication have not been disclosed.

This investigational ophthalmology product is being studied for its ability to:

  • Reduce injection frequency
  • Lower the risk of injection-associated complications, such as injury and infection

This is an investigational product in preclinical development. It has not been approved by the FDA for marketing in the U.S. for any indication.

DURECT has licensed worldwide rights to develop and commercialize a sustained-release ophthalmology product utilizing DURECT’s SABER technology to Santen Pharmaceutical Co., Ltd. For a description of the associated terms, please see Collaborations.

Learn more about SABER technology

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.